The Company regularly evaluates its business and objectives to ensure that it is properly configured and sized based on changing market conditions. Accordingly, the Company has implemented certain restructuring initiatives, including consolidation of certain facilities throughout the world and rationalization of its operations. In the second quarter of fiscal year 2026, management initiated a restructuring plan to right-size our cost base through a reduction of approximately 10% in global headcount, including both existing and planned positions, as well as additional non-labor cost reductions. As of May 31, 2026, the Company has incurred cumulative restructuring charges of $6.7 million for the fiscal year 2026 restructuring plan, which is completed. In the second quarter of fiscal year 2025, management initiated a restructuring plan primarily designed to focus the end market exposure and streamline operations of the Company's global genomics business, which was completed as of May 31, 2025.

The Company’s restructuring charges consist of severance payments, costs for outplacement services, and post-employment benefits (collectively, “employee separation costs”), other related exit costs and asset impairment charges related to restructuring activities. These amounts are partially recorded within cost of service revenues and partially recorded within general and administrative expense on the consolidated statements of operations.

Restructuring charges by segment were as follows:


	Year ended May 31,
	2026		2025
Food Safety	$	3.4	$	2.2
Animal Safety		0.6		7.4
Corporate		3.0		1.5
Total	$	7.0	$	11.1

Restructuring activity for the twelve months ended May 31, 2026 was as follows:


	Employee Separation Costs			Other Exit Costs			Total
Balance as of May 31, 2025	$	0.8		$	—		$	0.8
Expense		7.1			(0.1	)		7.0
Cash Payments		(7.3	)		—			(7.3	)
Asset impairments and other (1)		—			0.1			0.1
Balance as of May 31, 2026	$	0.6		$	—		$	0.6

(1) Asset impairments relate to charges incurred by the Company's Animal Safety operating segment and global genomics business.